Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

Researchers have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.

This news follows a recent Phase 3 trial where Keytruda®, another immunotherapy, failed to show similar benefits in the same setting. The success of Libtayo in this trial could represent a ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

This news follows a recent Phase 3 trial where Keytruda®, another immunotherapy, failed to show similar benefits in the same setting. The success of Libtayo in this trial could represent a significant ...

Several factors, including histopathologic subtypes of liver metastases, tumor-infiltrating lymphocyte (TIL) enrichment, and molecular subtypes, may help guide the identification of candidates for ...

Umoja Biopharma announced a $100 million Series C round that will help the Seattle-based company further develop its CAR T-cell immunotherapy treatments for cancer. Umoja is developing a multi ...

Get Instant Summarized Text (Gist) A phase 1 clinical trial indicates that a new off-the-shelf immunotherapy using CAR-NK cells shows promise for treating B-cell lymphomas. This approach, derived ...